GB2117647A - Medical treatment and apparatus therefor - Google Patents
Medical treatment and apparatus therefor Download PDFInfo
- Publication number
- GB2117647A GB2117647A GB08309311A GB8309311A GB2117647A GB 2117647 A GB2117647 A GB 2117647A GB 08309311 A GB08309311 A GB 08309311A GB 8309311 A GB8309311 A GB 8309311A GB 2117647 A GB2117647 A GB 2117647A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cells
- chamber
- sub
- membrane
- cellular material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A subcutaneously implantable diffusion chamber is proposed, the chamber housing hybrid living cells adapted to produce sub-cellular material capable of affording beneficial activity in the body for medical purposes and the chamber having a wall defined by a membrane which, in vivo, inhibits the free diffusion therethrough of the cells but not sub-cellular material. The cells can be of hybridoma form to produce monoclonal antibodies specific for tumours. The membrane acts to allow outward diffusion of the antibodies or other active sub-cellular material, to allow inward diffusion from the host body of oxygen, nutrients or other sub-cellular material to sustain the cell effectiveness, and to inhibit outward diffusion of the cells and prevents metastasis as a neoplastic growth or other undesirable results. The membrane preferably only passes material of up to about 0.2 mu m diameter. <IMAGE>
Description
SPECIFICATION
Medical treatment and apparatus therefor
Various proposals have been made for the production from living cells, modified to abnormal hybrid forms, of monoclonal antibodies specific for tumours, and for the use of such antibodies in diagnostic, monitoring and therapeutic applications.
However difficulties can arise in such applications.
One difficulty can arise from the fact that the antibodies are commonly short-lived and this is disadvantageous in relation to the time necessary for the separation and other preparation thereof appropriate to the relevant application. Another difficulty arises from the fact that the applications commonly involve intermittent extracorporeal administration whereas, for therapeutic applications at least, benefit may well derive from continuous administration.
Clearly, similar consequences can arise with other proposals for the use of hybrid living cells adapted to produce sub-cellular material capable of affording beneficial activity in the body.
An object of the present invention is to improve this situation and to this end there is provided a subcutaneously implantable diffusion chamber housing the hybrid cells, the chamber having a wall defined by a membrane which, in vivo, inhibits the free diffusion therethrough of the cells but not subcellular material.
Following implantation of the chamber in a patint, the membrane allows outward diffusion of antibodies out or other active sub-cellular material into the patient, and inward diffusion from the host body of oxygen, nutrients or other sub-cellular material necessary to sustain the effectiveness of the encapsulated cells. At the same time, the membrane inhibits outward diffusion of the cells themselves and so obviates the risk that these may metastasise as a neoplastic growth or cause other undesired results in the patient. For these purposes the membrane should preferably allow passage of material of diameter up to about 0.2us, but not higher.
Initial development of the invention has in fact involved the use of hybridoma cells to produce monoclonal antibodies specific for tumours, such cells being produced by fusing intratumoural lym phocytesfrom the subject tumour with a human myeloma line, and it is convenient to describe the invention further, by way of example, with reference to this development. Reference is also made to the accompanying drawings, in which:
Figure 1 schematically illustrates in cross section a chamber used in initial development of the invention, and
Figure 2 graphically illustrates a result of use of the chamber of Figure 1.
The chamber of Figure 1 has a main body 10 of generally hollow circular cylindrical form having one end wall, which body is closed at its other end by a filter 11. The body is made in two parts 12 and 13, the former of which is of similar shape to that of the overall body, while the latter is of sleeve form for threaded engagement about the side wall of part T2.
The sleeve part 13 has at its outer end a stepped inner flange 14 and an outer flange 15. The inner flange 14 supports a fenestrated filter support 16 and also, in association with the filter support, the filter 11. Around the periphery of the filter is located a succession of two O-rings 17 with a slip ring 18 therebetween, this succession being sealingly held, together with the filter, between the free end of the side wall of part 12 and the flange 14 when the chamber is assembled.
Remaining structural features of the chamber comprise inlet and outlet cannulae 19 and 20 projecting through the end wall of part 12 into and outwardly of the chamber.
In manufacture, the chamber 10 has been made up from materials and existing products of biologically acceptable forms. More specifically the body was made of a synthetic homopolymer, Delrin, the filter support is a 3cm diameter injection-moulded Millipore product, the filter is a Durapore product of nitro cellulose material and 0.22cm pore size, the O-rings and slip ring are existing products of rubber and nylon, and the cannulae are 21-gauge butterfly needles as used for intravenous injections. Clearly this construction can be varied.
Hybridoma cells housed in the chamber are denoted generally at 21, these cells having been produced as more particularly described in a communication entitled "Human Hybridomas from
Malignant Gliomas" by K. Sikora et alin The Lancet,
January 2,1982,
Trial of this chamber has involved subcutaneous implantation, with the cannulae projecting transcutancously outwardly into the upper anterior abdominal wall of a terminal patient, now deceased, with recurrent glioma. The procedure was carried out under local anaesthetic and the chamber secured by sutures passed through holes in the external flange 15. 108 human hybridoma cells previously prepared by the fusion of intratumoural lymphocytes from the patient's primary tumour were injected into the chamber in serum-free tissue culture medium.In addition, 107 cells which were pusle-labelled with 10011Ci L-(4,5-3H) lysine monohydrochloride, specific activity 80Ci/mmol (Amersham International) were also injected into the chamber. Such cells were shown to release internally labelled immunoglobulin for up to 48 hours. Serum samples were collected from the patient at regular intervals following insertion of the chamber and trichloroacetic acid precipitable 3H counts determined by scintillation counting.
The resultant counts are graphically illustrated in
Figure 2 and clearly show tritiated monoclonal antibody release into the blood steam in the three days following installation of the pulse-labelled cells.
Examination during this trial indicated no problems arising from the chamber during a period of three months in which it remained in situ. Specifically, there was no evidence of infection or of an inflammatory response around the chamber. Also, in pre-trial testing, there was no evidence of any spread of hybridoma cells outside the chamber as judged by scanning electron microscope examination of the filter after incubating the chamber filled with 108 cells in tissue culture medium for fourteen days.
Claims (5)
1. Asubcutaneously implantable diffusion charr ber housing hybrid living cells adapted to produce sub-cellular material capable of affording beneficial activity in the body, the chamber having a wall defined by a membrane which, in vivo, inhibits the free diffusion therethrough of said cells but not sub-cellular material.
2. A chamber according to Claim 1 wherein said cells are of hybridoma form adapted to produce monoclonal antibodies specific for tumours.
3. A chamber according to Claim 1 wherein said cells are formed by fusing intratumoural lymphocytes with a human myeloma line.
4. A chamber according to any preceding claim wherein said membrane only passes material of up to about 0.2pm diameter.
5. A chamber according to any preceding claim wherein said chamber comprises a hollowed body part and an annular body part, which parts are each made of a synthetic homopolymer and are threadably inter-engageable to retain therebetween a filter serving as said membrane.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08309311A GB2117647B (en) | 1982-04-06 | 1983-04-06 | Medical treatment and apparatus therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8210137 | 1982-04-06 | ||
GB08309311A GB2117647B (en) | 1982-04-06 | 1983-04-06 | Medical treatment and apparatus therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2117647A true GB2117647A (en) | 1983-10-19 |
GB2117647B GB2117647B (en) | 1985-06-19 |
Family
ID=26282482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08309311A Expired GB2117647B (en) | 1982-04-06 | 1983-04-06 | Medical treatment and apparatus therefor |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2117647B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001611A1 (en) * | 1994-07-08 | 1996-01-25 | Baxter International Inc. | Implanted device containing tumor cells for the treatment of cancer |
EP0746309A1 (en) * | 1993-03-01 | 1996-12-11 | GIAMPAPA, Vincent C. | Subcutaneous implantable multiple agent delivery system |
US6156305A (en) * | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
WO2005089671A1 (en) * | 2004-03-19 | 2005-09-29 | Microislet, Inc. | Implantable intravascular delivery device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB988794A (en) * | 1961-04-04 | 1965-04-14 | Bendix Corp | Electrical servo-system operating on an extended speed range |
GB1336264A (en) * | 1971-01-08 | 1973-11-07 | Ceskoslovenska Akademie Ved | Implant for diffusion of medicament and a method for its production |
-
1983
- 1983-04-06 GB GB08309311A patent/GB2117647B/en not_active Expired
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB988794A (en) * | 1961-04-04 | 1965-04-14 | Bendix Corp | Electrical servo-system operating on an extended speed range |
GB1336264A (en) * | 1971-01-08 | 1973-11-07 | Ceskoslovenska Akademie Ved | Implant for diffusion of medicament and a method for its production |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746309A1 (en) * | 1993-03-01 | 1996-12-11 | GIAMPAPA, Vincent C. | Subcutaneous implantable multiple agent delivery system |
EP0746309A4 (en) * | 1993-03-01 | 1997-06-25 | Vincent C Giampapa | Subcutaneous implantable multiple agent delivery system |
WO1996001611A1 (en) * | 1994-07-08 | 1996-01-25 | Baxter International Inc. | Implanted device containing tumor cells for the treatment of cancer |
AU699405B2 (en) * | 1994-07-08 | 1998-12-03 | Baxter International Inc. | Implanted device containing tumor cells for the treatment of cancer |
US6156305A (en) * | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
WO2005089671A1 (en) * | 2004-03-19 | 2005-09-29 | Microislet, Inc. | Implantable intravascular delivery device |
Also Published As
Publication number | Publication date |
---|---|
GB2117647B (en) | 1985-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4472500A (en) | Rat myeloma cell lines | |
US4378016A (en) | Artificial endocrine gland containing hormone-producing cells | |
US4350683A (en) | Antibody production from hybrid cell line | |
US5002661A (en) | Artificial pancreatic perfusion device | |
US5026365A (en) | Method and apparatus for therapeutically treating immunological disorders and disease states | |
US4372294A (en) | Method and apparatus for radiolabeling red blood cells | |
CA1144705A (en) | Implant device | |
US4491126A (en) | Method and apparatus for monitoring body parts of animals | |
US4724213A (en) | Murine hybridoma Lym-1 and diagnostic antibody produced thereby | |
US4242459A (en) | Cell culture device | |
WO1991000119A1 (en) | Implantable device | |
EP1435220A2 (en) | Process and device for facilitating the implantation of biological material | |
JPH05268986A (en) | Monoclonal antibody and activation of lymphocyte | |
IE46215B1 (en) | Production of specific immune nucleic acids cell dialysates and antibodies | |
CA1248892A (en) | Murine hybridoma lym-2 and diagnostic antibody produced thereby | |
GB2117647A (en) | Medical treatment and apparatus therefor | |
Sone et al. | A substrain of NZB mouse as an animal model of autoimmune inner ear disease | |
Rolstad et al. | The “natural resistance” to bone marrow allografts in normal and athymic nude rats Rapid cytotoxic reactions both in vivo and in vitro | |
CA1327168C (en) | Anti-trichomonas vaginalis monoclonal antibodies | |
Ghadirian et al. | Pathogenicity of axenically cultivated Entamoeba histolytica, strain 200: NIH, in the hamster | |
EP0428485B1 (en) | Novel antiidiotypic monoclonal antibodies | |
Sikora | The Characterisation of Gliomas Using Human Monoclonal Antibodies: Minireview on Cancer Research | |
EP0019167B1 (en) | Medicinal preparation for the treatment of carcinoma and process for preparing it | |
Byrne et al. | Aortitis caused by beta-lactamase producing Haemophilus influenzae type b. | |
Orbach-Arbouys et al. | Enhancement of immunological responses by methotrexate pretreatment as a result of an eventual elimination of suppressor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
PCNP | Patent ceased through non-payment of renewal fee |